Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
42 hedge funds and large institutions have $3.45M invested in Iterum Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
0.2% less ownership
Funds ownership: 0.43% → 0.23% (-0.2%)
5% less funds holding
Funds holding: 44 → 42 (-2)
87% less capital invested
Capital invested by funds: $26M → $3.45M (-$22.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$328K |
| 2 |
Franklin Resources
San Mateo,
California
|
+$316K |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
+$49.3K |
| 4 |
KF
Krilogy Financial
St. Louis,
Missouri
|
+$41.1K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$30.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$2.17M |
| 2 |
Millennium Management
New York
|
-$2M |
| 3 |
Two Sigma Investments
New York
|
-$1.22M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$269K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$207K |
ITRM Hedge Fund Activity: Q3 2021 in Review
42 of the 5,591 institutional investors tracked by Wall St. Rank reported a position in Iterum Therapeutics (ITRM) for Q3 2021, worth a combined $3.45M — down 87% from $26M a quarter earlier.
Fund positioning in ITRM was balanced in Q3 2021: 9 funds opened new positions, 9 closed out, 6 added to existing stakes and 6 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $328K. The largest seller was Renaissance Technologies, cutting an estimated $2.17M.
- 42 institutional investors held Iterum Therapeutics (ITRM) as of Q3 2021, down from 44 in Q2 2021.
- Funds reported $3.45M of Iterum Therapeutics stock for Q3 2021, down 87% quarter-over-quarter.
- 9 funds opened new Iterum Therapeutics positions in Q3 2021 and 9 closed out, a net change of 0 holders.
- The largest Iterum Therapeutics buyer in Q3 2021 was Morgan Stanley, an estimated $328K added.
- The largest Iterum Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $2.17M sold.
Based on aggregated 13F filings for Q3 2021.